CRI Worldwide, LLC.

Willingboro, New Jersey 08046

0 studies enrolling now · 19 studies all time

What they study most

Attention Deficit Hyperactivity Disorder, Back Pain Lower Back Chronic, Bipolar Depression, Chronic Low Back Pain, Chronic Nonmalignant and Nonneuropathic Pain, Cognitive Impairment Associated With Schizophrenia, Hepatitis C, Insomnia, Low Back Pain, Major Depressive Disorder, Schizophrenia, Schizophrenia and Predominant Negative Symptoms

Studies at this site

• Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms — Completed
• SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• Long Term Safety Study of Tanezumab in Chronic Low Back Pain — Stopped early
• Long-term Safety of Once-daily Hydrocodone Bitartrate (HYD) Tablets For Moderate to Severe Chronic Nonmalignant and Nonneuropathic Pain. Includes a 24-week Extension Period. — Completed
• Efficacy and Safety of Hydrocodone Bitartrate (HYD) in Subjects With Moderate to Severe Chronic Low Back Pain — Completed
• A Twelve Week, Open Label Extension Study in Patients With Schizophrenia — Completed
• Safety and Efficacy of Cariprazine in Patients With Schizophrenia — Completed
• An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia — Completed
• Double Blind, Randomized, 3 Week Inpatient Study To Evaluate The Safety & Efficacy Of PF-02545920 Compared With Placebo — Stopped early
• Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia — Completed
• A Study of RO4917838 in Participants With Persistent, Predominant Negative Symptoms of Schizophrenia (NN25310) — Completed
• Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression — Completed
• PEARL Schizophrenia Maintenance — Completed
• A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs) — Completed
• A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C — Completed
• Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia — Completed
• Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia — Status unconfirmed